Epicept Corporation (EPCT) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-21.04M
Depreciation and amortization	296K
Gain on disposal of assets
Foreign exchange (gain) loss
Stock-based compensation expense	1.66M
Excess inventory expense
Amortization of deferred financing costs and discount on loans	463K
Decrease (increase) in accounts receivable
Increase in inventory
(Increase) decrease in prepaid expenses and other current assets
Increase in accounts payable	1.22M
(Decrease) increase in accrued research contract costs
Increase (decrease) in other accrued liabilities	-751K
Increase in deferred revenue
Recognition of deferred revenue
Decrease in other liabilities
Net cash used in operating activities
Release of restricted cash in connection with conversion of 7.5556% convertible subordinated notes
Proceeds from sale of property and equipment
Purchases of property and equipment	-102K
Net cash provided by investing activities
Proceeds from exercise of stock options and warrants
Proceeds from issuance of common stock and warrants, net of issuance costs
Proceeds from loans and warrants
Deferred financing costs	0
Repayment of loans	-808K
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase in cash and cash equivalents	-4.23M
Cash and cash equivalents at beginning of year	4.54M
Cash and cash equivalents at end of period	317K
Cash paid for interest	327K
Cash paid for income taxes	81K
Unpaid costs associated with issuance of common stock
Unpaid financing costs

Entities mentioned with EPCT

View All Entities